Fiber-optic triggered release of liposome in vivo: Implication of personalized chemotherapy

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 5171-5185

  Huang, Huei Ling ^a   Lu, Pei Hsuan ^a   Yang, Hung Chih ^a   Lee, Gi Da ^a,b   Li, Han Ru ^a   Liao, Kuo Chih ^a  

^a NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Fiber optic guided excitation; Gold nanoparticles; Light excitation triggered release; Photo thermal responsive liposome; Tunable release in vivo

Indexed keywords

1 MYRISTOYL 2 PALMITOYL SN GLYCERO 3 PHOSPHOTYDILCHOLINE; 1,2 DIPALMITOYL SN GLYCERO 3 PHOSPHATIDYLCHOLINE; 1,2 DISTEAROYL SN GLYCERO 3 PHOSPHATIDYLCHOLINE; 1,2 DISTEAROYL SN GLYCERO 3 PHOSPHOETHANOLAMINE N [METHOXY(POLYETHYLENE GLYCOL) 2000]; FLUORESCEIN; GOLD NANOPARTICLE; LIPOSOME; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; FLUORESCENT DYE; GLASS FIBER; GOLD; METAL NANOPARTICLE; SOLVENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG RELEASE; DRUG RETENTION; DRUG STRUCTURE; ENCAPSULATION; EXCITATION; FIBER OPTIC GUIDED LASER EXCITATION; FIBER OPTICS; FLUORESCENCE; FLUORESCENCE IMAGING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NANOANALYSIS; NONHUMAN; PARTICLE SIZE; PERSONALIZED MEDICINE; PHOTOCHEMOTHERAPY; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; DRUG SCREENING; HEAT; LASER; LIGHT; NEOPLASMS; NUDE MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; FIBER OPTIC TECHNOLOGY; FLUORESCEIN; FLUORESCENT DYES; GOLD; HOT TEMPERATURE; HUMANS; LASERS; LIGHT; LIPOSOMES; MALE; METAL NANOPARTICLES; MICE; MICE, NUDE; NEOPLASMS; OPTICAL FIBERS; SOLVENTS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84939640855     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S85915     Document Type: Article

References (42)

1. Qin YY, Li H, Guo XJ, et al. Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30,698 patients. PLoS One. 2011;6(11):e26946.
2. Kim R, Osaki A, Toge T. Current and future roles of neoadjuvant chemotherapy in operable breast cancer. Clin Breast Cancer. 2005;6(3): 223–232.
3. Swain SM. Chemotherapy: updates and new perspectives. Oncologist. 2011;16(supp 1):30–39.
4. Dickerson EB, Dreaden EC, Huang X, et al. Gold nanorod assisted near-infrared plasmonic photothermal therapy (PPTT) of squamous cell carcinoma in mice. Cancer Lett. 2008;269(1):57–66.
5. Hazard HW, Gorla SR, Scholtens D, Kiel K, Gradishar WJ, Khan SA. Surgical resection of the primary tumor, chest wall control, and survival in women with metastatic breast cancer. Cancer. 2008;113(8): 2011–2019.
6. Gnerlich J, Jeffe DB, Deshpande AD, Beers C, Zander C, Margenthaler JA. Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1988–2003 SEER data. Ann Surg Oncol. 2007;14(8):2187–2194.
7. Rapiti E, Verkooijen HM, Vlastos G, et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol. 2006;24(18):2743–2749.
8. Gurney H. How to calculate the dose of chemotherapy. Br J Cancer. 2002;86(8):1297–1302.
9. Hunter RJ, Navo MA, Thaker PH, Bodurka DC, Wolf JK, Smith JA. Dosing chemotherapy in obese patients: actual versus assigned body surface area (BSA). Cancer Treat Rev. 2009;35(1):69–78.
10. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther. 2008;83(5):761–769.
11. O’Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15(3):440–449.
12. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001; 19(14):3312–3322.
13. Lyass O, Uziely B, Ben-Yosef R, et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer. 2000;89(5):1037–1047.
14. Dos Santos N, Allen C, Doppen AM, et al. Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding. Biochim Biophys Acta. 2007; 1768(6):1367–1377.
15. Gabizon AA. Liposome circulation time and tumor targeting: implications for cancer chemotherapy. Adv Drug Deliv Rev. 1995;16(2–3):285–294.
16. Alaouie AM, Sofou S. Liposomes with triggered content release for cancer therapy. J Biomed Nanotechnol. 2008;4(3):234–244.
17. Kong G, Anyarambhatla G, Petros WP, et al. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res. 2000;60(24):6950–6957.
18. Huang SK, Stauffer PI, Hong K, et al. Liposomes and hyperthermia in mice: increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes. Cancer Res. 1994;54(8):2186–2191.
19. Zasadzinski JA, Wong B, Forbes N, Braun G, Wu G. Novel methods of enhanced retention in and rapid, targeted release from liposomes. Curr Opin Colloid Interface Sci. 2011;16(3):203–214.
20. Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD, Bally MB. The liposomal formulation of doxorubicin. Methods Enzymol. 2005;391:71–97.
21. Bibi S, Lattmann E, Mohammed AR, Perrie Y. Trigger release liposome systems: local and remote controlled delivery. J Microencapsul. 2012;29(3):262–276.
22. O’Kelly J, Liao KC, Clifton W, Lu D, Koeffler P, Loeb G. Percutaneous fiber-optic sensor for the detection of chemotherapy-induced apoptosis in vivo. Proc SPIE. 2010;7555:75551H.
23. Liao KC, Chiu HS, Fan SY, Zheng YD, Lu PH. Percutaneous fiber-optic biosensor for immediate evaluation of chemotherapy efficacy in vivo (part I): Strategy of assay design for monitoring non-homogeneously distributed biomarkers. Sensor Actuat B-Chemical. 2015.
24. Fan SY, Chiu HS, Lin TY, Liao A, Liao KC. Percutaneous fiber-optic biosensor for immediate evaluation of chemotherapy efficacy in vivo (part II): In vitro and in vivo characterizations. Sensor Actuat B-Chemical. 2015.
25. Derfus AM, von Maltzahn G, Harris TJ, et al. Remotely triggered release from magnetic nanoparticles. Adv Mater. 19(22):3932–3936.
26. Needham D, Dewhirst MW. The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv Drug Deliv Rev. 2001;53(3):285–305.
27. Needham D, Anyarambhatla G, Kong G, Dewhirst MW. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Discov. 2000;60(5):1197–1201.
28. Liao KC, Hogen-Esch T, Richmond FJ, Marcu L, Clifton W, Loeb GE. Percutaneous fiber-optic sensor for chronic glucose monitoring in vivo. Biosens Bioelectron. 2008;23(10):1458–1465.
29. Liao KC, Chang SC, Chiu CY, Chou YH. Acute response in vivo of a fiber-optic sensor for continuous glucose monitoring from canine studies on point accuracy. Sensors. 2010;10(8):7789–7802.
30. Agostinis P, Berg K, Cengel KA, et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin. 2011;61(4):250–281.
31. Li JL, Gu M. Gold-nanoparticle-enhanced cancer photothermal therapy. IEEE J Top Quantum Electron. 2010;16(4):989–996.
32. Patra CR, Bhattacharya R, Mukhopadhyay D, Mukherjee P. Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Adv Drug Deliv Rev. 2010;62(3):346–361.
33. Chang HI, Yeh MK. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomedicine. 2012;7:49–60.
34. Weinstein JN, Yoshikami S, Henkart P, Blumenthal R, Hagins WA. Liposome-cell interaction: transfer and intracellular release of a trapped fluorescent marker. Science. 1977;195(4277):489–492.
35. Jana NR, Peng X. Single-phase and gram-scale routes toward nearly monodisperse Au and other noble metal nanocrystals. J Am Chem Soc. 2003;125(47):14280–14281.
36. Liu X, Atwater M, Wang J, Huo Q. Extinction coefficient of gold nanoparticles with different sizes and different capping ligands. Colloids Surface B Biointerfaces. 2007;58(1):3–7.
37. Hope MJ, Bally MB, Webb G, Cullis PR. Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of size, trapped volume and ability to maintain a membrane potential. Biochim Biophys Acta. 1985;812(1):55–65.
38. MacDonald RC, MacDonald RI, Menco BP, Takeshita K, Subbarao NK, Hu LR. Small-volume extrusion apparatus for preparation of large, unilamellar vesicles. Biochim Biophys Acta. 1991;1061(2): 297–303.
39. Paasonen L, Laaksonen T, Johans C, Yliperttula M, Kontturi K, Urtti A. Gold nanoparticles enable selective light-induced contents release from liposomes. J Control Release. 2007;122(1):86–93.
40. Wu G, Mikhailovsky A, Khant HA, Fu C, Chiu W, Zasadzinski JA. Remotely triggered liposome release by near-infrared light absorption via hollow gold nanoshells. J Am Chem Soc. 2008;130(26): 8175–8177.
41. Troutman TS, Leung SJ, Romanowski M. Light-induced content release from plasmon-resonant liposomes. Adv Mater. 2009;21(22): 2334–2338.
42. Leung SJ, Kachur XM, Bobnick MC, Romanowski M. Wavelength-selective light-induced release from plasmon resonant liposomes. Adv Funct Mater. 2011;21(6):1113–1121.